Cargando…

Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study

Our previous clinical trial showed that a novel concentrated herbal extract formula, YH1 (Rhizoma coptidis and Shen-Ling-Bai-Zhu-San), improved blood glucose and lipid control. This pilot observational study investigated whether YH1 affects microbiota, plasma, and fecal bile acid (BA) compositions i...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yueh-Hsiang, Wu, Yi-Hong, Tang, Hsiang-Yu, Chen, Szu-Tah, Wang, Chih-Ching, Ho, Wan-Jing, Lin, Yi-Hsuan, Liu, Geng-Hao, Lin, Pei-Yeh, Lo, Chi-Jen, Yeh, Yuan-Ming, Cheng, Mei-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505101/
https://www.ncbi.nlm.nih.gov/pubmed/36145605
http://dx.doi.org/10.3390/pharmaceutics14091857
_version_ 1784796388299636736
author Huang, Yueh-Hsiang
Wu, Yi-Hong
Tang, Hsiang-Yu
Chen, Szu-Tah
Wang, Chih-Ching
Ho, Wan-Jing
Lin, Yi-Hsuan
Liu, Geng-Hao
Lin, Pei-Yeh
Lo, Chi-Jen
Yeh, Yuan-Ming
Cheng, Mei-Ling
author_facet Huang, Yueh-Hsiang
Wu, Yi-Hong
Tang, Hsiang-Yu
Chen, Szu-Tah
Wang, Chih-Ching
Ho, Wan-Jing
Lin, Yi-Hsuan
Liu, Geng-Hao
Lin, Pei-Yeh
Lo, Chi-Jen
Yeh, Yuan-Ming
Cheng, Mei-Ling
author_sort Huang, Yueh-Hsiang
collection PubMed
description Our previous clinical trial showed that a novel concentrated herbal extract formula, YH1 (Rhizoma coptidis and Shen-Ling-Bai-Zhu-San), improved blood glucose and lipid control. This pilot observational study investigated whether YH1 affects microbiota, plasma, and fecal bile acid (BA) compositions in ten untreated male patients with type 2 diabetes (T2D), hyperlipidemia, and a body mass index ≥ 23 kg/m(2). Stool and plasma samples were collected for microbiome, BA, and biochemical analyses before and after 4 weeks of YH1 therapy. As previous studies found, the glycated albumin, 2-h postprandial glucose, triglycerides, total cholesterol, and low-density lipoprotein cholesterol levels were significantly improved after YH1 treatment. Gut microbiota revealed an increased abundance of the short-chain fatty acid-producing bacteria Anaerostipes and Escherichia/Shigella. Furthermore, YH1 inhibited specific phylotypes of bile salt hydrolase-expressing bacteria, including Parabacteroides, Bifidobacterium, and Bacteroides caccae. Stool tauro-conjugated BA levels increased after YH1 treatment. Plasma total BAs and 7α-hydroxy-4-cholesten-3-one (C4), a BA synthesis indicator, were elevated. The reduced deconjugation of BAs and increased plasma conjugated BAs, especially tauro-conjugated BAs, led to a decreased glyco- to tauro-conjugated BA ratio and reduced unconjugated secondary BAs. These results suggest that YH1 ameliorates T2D and hyperlipidemia by modulating microbiota constituents that alter fecal and plasma BA compositions and promote liver cholesterol-to-BA conversion and glucose homeostasis.
format Online
Article
Text
id pubmed-9505101
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95051012022-09-24 Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study Huang, Yueh-Hsiang Wu, Yi-Hong Tang, Hsiang-Yu Chen, Szu-Tah Wang, Chih-Ching Ho, Wan-Jing Lin, Yi-Hsuan Liu, Geng-Hao Lin, Pei-Yeh Lo, Chi-Jen Yeh, Yuan-Ming Cheng, Mei-Ling Pharmaceutics Article Our previous clinical trial showed that a novel concentrated herbal extract formula, YH1 (Rhizoma coptidis and Shen-Ling-Bai-Zhu-San), improved blood glucose and lipid control. This pilot observational study investigated whether YH1 affects microbiota, plasma, and fecal bile acid (BA) compositions in ten untreated male patients with type 2 diabetes (T2D), hyperlipidemia, and a body mass index ≥ 23 kg/m(2). Stool and plasma samples were collected for microbiome, BA, and biochemical analyses before and after 4 weeks of YH1 therapy. As previous studies found, the glycated albumin, 2-h postprandial glucose, triglycerides, total cholesterol, and low-density lipoprotein cholesterol levels were significantly improved after YH1 treatment. Gut microbiota revealed an increased abundance of the short-chain fatty acid-producing bacteria Anaerostipes and Escherichia/Shigella. Furthermore, YH1 inhibited specific phylotypes of bile salt hydrolase-expressing bacteria, including Parabacteroides, Bifidobacterium, and Bacteroides caccae. Stool tauro-conjugated BA levels increased after YH1 treatment. Plasma total BAs and 7α-hydroxy-4-cholesten-3-one (C4), a BA synthesis indicator, were elevated. The reduced deconjugation of BAs and increased plasma conjugated BAs, especially tauro-conjugated BAs, led to a decreased glyco- to tauro-conjugated BA ratio and reduced unconjugated secondary BAs. These results suggest that YH1 ameliorates T2D and hyperlipidemia by modulating microbiota constituents that alter fecal and plasma BA compositions and promote liver cholesterol-to-BA conversion and glucose homeostasis. MDPI 2022-09-02 /pmc/articles/PMC9505101/ /pubmed/36145605 http://dx.doi.org/10.3390/pharmaceutics14091857 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Huang, Yueh-Hsiang
Wu, Yi-Hong
Tang, Hsiang-Yu
Chen, Szu-Tah
Wang, Chih-Ching
Ho, Wan-Jing
Lin, Yi-Hsuan
Liu, Geng-Hao
Lin, Pei-Yeh
Lo, Chi-Jen
Yeh, Yuan-Ming
Cheng, Mei-Ling
Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study
title Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study
title_full Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study
title_fullStr Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study
title_full_unstemmed Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study
title_short Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study
title_sort gut microbiota and bile acids mediate the clinical benefits of yh1 in male patients with type 2 diabetes mellitus: a pilot observational study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505101/
https://www.ncbi.nlm.nih.gov/pubmed/36145605
http://dx.doi.org/10.3390/pharmaceutics14091857
work_keys_str_mv AT huangyuehhsiang gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy
AT wuyihong gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy
AT tanghsiangyu gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy
AT chenszutah gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy
AT wangchihching gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy
AT howanjing gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy
AT linyihsuan gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy
AT liugenghao gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy
AT linpeiyeh gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy
AT lochijen gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy
AT yehyuanming gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy
AT chengmeiling gutmicrobiotaandbileacidsmediatetheclinicalbenefitsofyh1inmalepatientswithtype2diabetesmellitusapilotobservationalstudy